CORT Corcept Therapeutics Inc

$CORT Shorts have knocked Corcept stock from $126 to $110 by slamming at open and close every day. They use algorithms to trick automated trading systems and unsophisticated investors. This creates opportunity for the intelligent investor. There are at least 5 distinct catalysts coming up in next two months, any one of which can spike stock north of $200 overnight. (1) Positive cancer results. CORT just had the second best oncology launch in history. More positive data before year end would expand the indication from $1 to $5 billion in potential market. (2) Relacorilant approval in Cushing’s. FDA rejection is expected and baked in to the current share price. A FDA reversal and surprise approval could add $75 to stock overnight. (3) Positive MASH results. Game changer. MASH is huge indication, and if CORT has a viable MASH drug they will likely great taken out well north of $200/sh. This could add $100 to stock overnight. Big pharma needs this.

$CORT Someone bought 2566 contracts of the Jan 27 120 strike calls yesterday for 13.50 each, that is a 3.5mm bet on Cort being well above 133.50 in a few months. That kind of bet on Cort options definitely stands out.

$CORT looks like the Monarch ph2b mash study was completed 9/29. I wonder how long before we see top line data? Should be before next earnings report I hope.

$CORT With 9.4M shares shorted, which is about 9% outstanding or 11% float, we will only trade sideways for a while until the next catalysts such as Relacorilant/CS approval in US, Lifyorli approval in EU, and/or Q3 ER - all in 2027. These catalysts should advance SP to north of $150. More exciting are the clinical advancement of Dazucorilant/ALS and Miricorilant/MASH to P3 trials. Hopefully, at least one of the two will be in H1/27, or both. The initiation of these two P3 trials will further advance SP to above $200. Then in 2028, we should see all four franchises firing - CS, PROC, ALS, and MASH, which are all $B- dollar blockbuster drugs. If not acquired and no split by then, we should see SP reaches north of $300. GL & cheers!

$CORT So, it looks like there is more support for difficult to control Type 2 diabetes actually being misdiagnosed cushings/hypercortisolism. If that is the case and roughly a quarter of the difficult to control Type 2 diabetes patients should be given Korlym/Relacorilant, what does that bring the TAM to???

$CORT Short-term catalysts are coming: Early Nov. - Q3 ER (Lifyorli sales ramp, record revenue, clinical development updates) Mid Dec. - Relacorilant/CS approval (Resubmitted on on 6/17, FDA accelerated approval possible in Nov.) EOY 2026 - Start of P3 trial for Dazucorilant/ALS EOY 2027 - Readout of Miricorilant/MASH P2b trial With only 2.5 months left, a busy catalyst calendar indeed. These will propel the SP to $150 territory or higher. GLTA and cheers!

$CORT maybe the TAM calc goes something like: A. US T2D patients on intensive insulin = 4m B. 24% hypercortisolism prevalence (per CATALYST) = 24% C. Authorized generic pricing of $120-210k (30-60% discount vs $300K Korlym list price…Relacorilant would be even higher) TAM = A x B x C = 4m x 24% x $120-210k/yr = $115-202b If that’s remotely right, then all the sudden a $3-5b sales outlook from Cushing’s alone (others have already posted about the many other indications CORT has or is pursuing) doesn’t seem so outrageous. Of course, obstacles include Relacorilant approval, screening adoption, payer coverage, competition, etc. Not a layup. Since 2018, median pharma M&A has been at FV/sales of 9.3x for FY1, 5.2x for FY3 and 3.8x for FY4. At $4B/yr (mid of range) for cushings alone x 3.8x for 4 years out to 2030 = $15B in value TODAY just for cushings. $15B / 108m shares = $139 per share TODAY for cushings alone. At 9.3x in 2030, that is $344/share ON CUSHINGS ALONE

$CORT By year end, we should hear from FDA and EMA about Relacorilant for, respectively, CS and PROC. Approval for CS in US would double the Korlym/Relacorilant franchise's reveven to $2B annually, and approval for PROC in EU would more than double the cohorts of PROC from 200K to 400K, which similarly doubles the PROC franchise's revenue to$2B annually. The story does not end there, coming 2027 would bring about two more major franchasises for CORT, they are: Dazucorilant for ALS and Miricorilant for MASH. Dazucorilant has been proven and shown to significantly prolong the lives of ALS sufferers, and Miricorilant has shown more than effective to cure fatty liver, but perhaps too effective with adverse side effects. The current tritration study of Miricorilant is to find the optimal doage of Miricorilant for efficacy and suppressed l side effects. When these two franchasises are added, CORT's valuation will be skyrocketed to north of $300 with franchasises for CS, OC, ALS and MASH.

$CORT this is a pretty big pull back. Market is down as a whole though. Any news I’m missing?

$CORT interesting that back in 2012 after fda approval analysts were only targeting $7. $10K back in 2012 would be worth $900K today Much smaller market too than… $CELC Cort doubled in a year after fda approval and then tripled in 3 years

$CORT Latest company news, Oct 20, 2026: the 2026 ADA/EASD consensus report recommends screening for hypercortisolism in patients with difficult-to-control type 2 diabetes, citing the CATALYST study, which found hypercortisolism in 24% of 1,057 patients. More news in our $CORT stock hub on Merlintrader. Not investment advice.

That insider sale is a headline, not a thesis imo. The real date on $CORT is Dec 17 2026, relacorilant PDUFA in hypercortisolism after the resubmission in June.

$CORT Maduck retires. Did he do so because his 10b5-1 recently reached a set price (maybe 125) and cashed him out of 170k options or did his 10b5-1 have him exercise 170K options regardless of price in contemplation of retirement ?